These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 15998635)

  • 1. Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs.
    Bykov VJ; Issaeva N; Zache N; Shilov A; Hultcrantz M; Bergman J; Selivanova G; Wiman KG
    J Biol Chem; 2005 Aug; 280(34):30384-91. PubMed ID: 15998635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound.
    Bykov VJ; Issaeva N; Shilov A; Hultcrantz M; Pugacheva E; Chumakov P; Bergman J; Wiman KG; Selivanova G
    Nat Med; 2002 Mar; 8(3):282-8. PubMed ID: 11875500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute cytotoxicity of MIRA-1/NSC19630, a mutant p53-reactivating small molecule, against human normal and cancer cells via a caspase-9-dependent apoptosis.
    Bou-Hanna C; Jarry A; Lode L; Schmitz I; Schulze-Osthoff K; Kury S; Bezieau S; Mosnier JF; Laboisse CL
    Cancer Lett; 2015 Apr; 359(2):211-7. PubMed ID: 25617798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Restoring p53 active conformation by zinc increases the response of mutant p53 tumor cells to anticancer drugs.
    Puca R; Nardinocchi L; Porru M; Simon AJ; Rechavi G; Leonetti C; Givol D; D'Orazi G
    Cell Cycle; 2011 May; 10(10):1679-89. PubMed ID: 21508668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reactivation of mutant p53 by capsaicin, the major constituent of peppers.
    Garufi A; Pistritto G; Cirone M; D'Orazi G
    J Exp Clin Cancer Res; 2016 Sep; 35(1):136. PubMed ID: 27599722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rescue of the apoptotic-inducing function of mutant p53 by small molecule RITA.
    Zhao CY; Grinkevich VV; Nikulenkov F; Bao W; Selivanova G
    Cell Cycle; 2010 May; 9(9):1847-55. PubMed ID: 20436301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutant p53 targeting by the low molecular weight compound STIMA-1.
    Zache N; Lambert JM; Rökaeus N; Shen J; Hainaut P; Bergman J; Wiman KG; Bykov VJ
    Mol Oncol; 2008 Jun; 2(1):70-80. PubMed ID: 19383329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reactivation of mutant p53: molecular mechanisms and therapeutic potential.
    Selivanova G; Wiman KG
    Oncogene; 2007 Apr; 26(15):2243-54. PubMed ID: 17401433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TAR1, a human anti-p53 single-chain antibody, restores tumor suppressor function to mutant p53 variants.
    Orgad S; Dimant H; Dor-On E; Azriel-Rosenfeld R; Benhar I; Solomon B
    J Immunother; 2010; 33(2):146-54. PubMed ID: 20139776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allele-specific p53 mutant reactivation.
    Yu X; Vazquez A; Levine AJ; Carpizo DR
    Cancer Cell; 2012 May; 21(5):614-625. PubMed ID: 22624712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small molecule MIRA-1 induces in vitro and in vivo anti-myeloma activity and synergizes with current anti-myeloma agents.
    Saha MN; Chen Y; Chen MH; Chen G; Chang H
    Br J Cancer; 2014 Apr; 110(9):2224-31. PubMed ID: 24691427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Restoring p53-dependent tumor suppression.
    Wang W; Rastinejad F; El-Deiry WS
    Cancer Biol Ther; 2003; 2(4 Suppl 1):S55-63. PubMed ID: 14508081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Restoring wild-type conformation and DNA-binding activity of mutant p53 is insufficient for restoration of transcriptional activity.
    Brazda V; Muller P; Brozkova K; Vojtesek B
    Biochem Biophys Res Commun; 2006 Dec; 351(2):499-506. PubMed ID: 17070499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective killing of human breast cancer cells by the styryl lactone (R)-goniothalamin is mediated by glutathione conjugation, induction of oxidative stress and marked reactivation of the R175H mutant p53 protein.
    Punganuru SR; Madala HR; Arutla V; Srivenugopal KS
    Carcinogenesis; 2018 Dec; 39(11):1399-1410. PubMed ID: 30010803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rescue of mutant p53 transcription function by ellipticine.
    Peng Y; Li C; Chen L; Sebti S; Chen J
    Oncogene; 2003 Jul; 22(29):4478-87. PubMed ID: 12881704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological reactivation of mutant p53: from protein structure to the cancer patient.
    Wiman KG
    Oncogene; 2010 Jul; 29(30):4245-52. PubMed ID: 20498645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reactivation of mutant p53: a new strategy for cancer therapy.
    Selivanova G; Kawasaki T; Ryabchenko L; Wiman KG
    Semin Cancer Biol; 1998; 8(5):369-78. PubMed ID: 10101802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small-molecule modulators of p53 family signaling and antitumor effects in p53-deficient human colon tumor xenografts.
    Wang W; Kim SH; El-Deiry WS
    Proc Natl Acad Sci U S A; 2006 Jul; 103(29):11003-8. PubMed ID: 16835297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 mutant-type in human prostate cancer cells determines the sensitivity to phenethyl isothiocyanate induced growth inhibition.
    Aggarwal M; Saxena R; Asif N; Sinclair E; Tan J; Cruz I; Berry D; Kallakury B; Pham Q; Wang TTY; Chung FL
    J Exp Clin Cancer Res; 2019 Jul; 38(1):307. PubMed ID: 31307507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reactivation of wild-type and mutant p53 by tryptophanolderived oxazoloisoindolinone SLMP53-1, a novel anticancer small-molecule.
    Soares J; Raimundo L; Pereira NA; Monteiro Â; Gomes S; Bessa C; Pereira C; Queiroz G; Bisio A; Fernandes J; Gomes C; Reis F; Gonçalves J; Inga A; Santos MM; Saraiva L
    Oncotarget; 2016 Jan; 7(4):4326-43. PubMed ID: 26735173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.